Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 25, Number 2—February 2019


Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil

Fernando A. Bozza1, Andres Moreira-Soto1, Alexandra Rockstroh, Carlo Fischer, Alessandra D. Nascimento, Andrea S. Calheiros, Christian Drosten, Patrícia T. Bozza, Thiago Moreno L. Souza, Sebastian Ulbert, and Jan Felix DrexlerComments to Author 
Author affiliations: National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil (F.A. Bozza, A.D. Nascimento); D’Or Institute for Research and Education, Rio de Janeiro (F.A. Bozza, A.D. Nascimento); Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany (A. Moreira-Soto, C. Fischer, C. Drosten, J.F. Drexler); Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany (A. Rockstroh, S. Ulbert); Instituto Oswaldo Cruz, Rio de Janeiro (A.S. Calheiros, P.T. Bozza); German Centre for Infection Research, Berlin (C. Drosten, J.F. Drexler); Center for Technological Development in Health, Rio de Janeiro (T.M.L. Souza); Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Sechenov University, Moscow, Russia (J.F. Drexler)

Cite This Article


Highlight and copy the desired format.

EID Bozza FA, Moreira-Soto A, Rockstroh A, Fischer C, Nascimento AD, Calheiros AS, et al. Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil. Emerg Infect Dis. 2019;25(2):311-315.
AMA Bozza FA, Moreira-Soto A, Rockstroh A, et al. Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil. Emerging Infectious Diseases. 2019;25(2):311-315. doi:10.3201/eid2502.180166.
APA Bozza, F. A., Moreira-Soto, A., Rockstroh, A., Fischer, C., Nascimento, A. D., Calheiros, A. S....Drexler, J. (2019). Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil. Emerging Infectious Diseases, 25(2), 311-315.


In seroconversion panels obtained from patients from Brazil, diagnostic testing for Zika virus infection was improved by combining multiple antibody isotypes, techniques, and antigens, but sensitivity remained suboptimal. In contrast, chikungunya virus diagnostic testing was unambiguous. Recurrent recent arbovirus infections suggested by serologic data and unspecific symptoms highlight the need for exhaustive virologic testing.

In 2013, Zika virus and chikungunya virus (CHIKV) emerged in Latin America (1,2). Their overlapping symptoms challenge accurate diagnosis on the basis of clinical manifestations (3). Direct Zika virus and CHIKV detection is limited to the acute phase of infection (4). Serologic detection of Zika virus–specific antibodies is hampered by low specificity and sensitivity of tests because of immune responses elicited by prior infection with other endemic flaviviruses (e.g., dengue virus [DENV]) (5,6). In addition, lack of adequate specimens limits studies evaluating the performance of diagnostic tests in tropical areas (7,8). To evaluate these challenges, we analyzed virus shedding and antibody responses over time in patients in Brazil sampled during the 2016 Zika virus and CHIKV outbreaks.

The Study

Figure 1

Thumbnail of Overview of diagnostic testing and shedding dynamics for Zika virus and CHIKV among patients in Brazil, 2016. A) Timeline of sampling and number of samples for each test. B, C) Zika virus (B) and CHIKV (C) loads in different body fluids at 1–5 and 5–9 dpo. Black dots indicate single samples. Red dots indicate samples taken 1–5 dpo that were negative 5–9 dpo. Dotted lines indicate paired samples that were positive at both time points. Bold line indicates the median. D, E) Viral loads

Figure 1. Overview of diagnostic testing and shedding dynamics for Zika virus and CHIKV among patients in Brazil, 2016. A) Timeline of sampling and number of samples for each test. B, C) Zika...

We prospectively sampled patients in 4 time points up to 90 days post–symptom onset (dpo) (Table 1; Figure 1, panel A; Appendix). The cohort comprised 15 patients with acute Zika virus infection (5 male, 10 female; median age 39.0 years [interquartile range 31.0–44.0 years]) and 18 patients with acute CHIKV infection (10 male, 8 female; median age 39.0 years [interquartile range 31.0–57.3 years]), determined by detection of viral RNA in blood or urine 1–9 dpo (Appendix Figures 1, 2). All Zika virus belonged to the Asian lineage (2), and all CHIKV to the East/Central/South African lineage, according to envelope-based typing.

At enrollment, Zika virus patients most frequently reported fever, rash, and arthralgia (80% each), and CHIKV patients most frequently reported arthralgia (100%), fever (89%), and myalgia (89%) (Table 2). No co-infection with Zika virus, CHIKV, or DENV was detected by real-time reverse transcription PCR (rRT-PCR). However, serologic analyses found that 4 (27%) Zika virus–infected patients also had CHIKV IgM at enrollment, and 1 (7%) had DENV IgM (Appendix Table 1, Figure 3). Similarly, 3 (17%) CHIKV-infected patients had Zika virus IgM, and 4 (22%) CHIKV-infected patients had DENV IgM at enrollment (Appendix Figure 4). We cannot exclude the possibility of cross-reactivity between Zika virus–specific and DENV-specific antibodies because 2 CHIKV patients simultaneously showed Zika virus and DENV IgM in an envelope-based ELISA (Appendix Table 2). Seventy-nine percent of Zika virus and 83% of CHIKV patients showed serologic evidence for past DENV infection at enrollment (Appendix Figures 1, 2). Thus, recent infections with heterologous arboviruses might bias attributing infection-specific symptoms for Zika virus and CHIKV.

Consistent with previous studies (4,9), Zika virus loads in serum and urine were low up to 9 dpo (≈104 RNA copies/mL) (Figure 1, panel B), whereas CHIKV loads were high ≈100-fold higher (≈106 RNA copies/mL) (Figure 1, panel C). However, unlike with Zika virus, CHIKV loads decreased significantly (p<0.001 by t test) from 5 dpo onward, and viral loads in urine were consistently low (Figure 1, panels D, E).

Figure 2

Thumbnail of Zika virus and CHIKV antibody dynamics among samples from patients in Brazil, 2016. A) Percentage seroconversion for markers of acute infection with Zika virus and CHIKV (IgM NS1–based Zika virus ELISA, IgM envelope-based Zika virus ELISA, IgM μ-capture Zika virus ELISA, IgA NS1-based Zika virus ELISA, IgM CHIKV ELISA) at any time point. B) Median ELISA ratios for Zika virus and CHIKV IgM and IgA over time. C) Percentage seroconversion for markers of convalescence after Zika virus a

Figure 2. Zika virus and CHIKV antibody dynamics among samples from patients in Brazil, 2016. A) Percentage seroconversion for markers of acute infection with Zika virus and CHIKV (IgM NS1–based Zika virus ELISA,...

Next, to assess the antibody kinetics of Zika virus and CHIKV, we measured antibody responses over time by commercial and in-house serologic tests. In a widely used nonstructural (NS) protein 1 antigen-based ELISA, Zika virus IgM seroconversion was low (33% [5/15]), whereas CHIKV IgM seroconversion was 100% using an envelope-based ELISA (p<0.0001 by Fisher exact test) (Figure 2, panel A; Appendix Tables 1, 2). Use of an in-house envelope-based ELISA increased the Zika virus IgM detection rate to 50% (7/14), and use of a commercially available μ-capture ELISA increased it to 43% (6/14) (Figure 2, panel A). Despite differential sensitivity, concordant results from different assays suggest comparable specificity of IgM detection (Appendix Table 1). The use of NS1-based IgA as a marker of acute infection increased the detection rate to 53% (8/15) over that of the NS1-based IgM ELISA. All IgM-positive patients also showed IgA, which increased during acute and subacute phases of infection and decreased during convalescence (Figure 2, panel B; Appendix Figure 3). This finding supports the usability of IgA-based serologic methods as an alternative or additional marker to IgM-based methods to detect acute Zika virus infection. The detection rate increased 2-fold when we used NS1-based IgA from when we used NS1-based IgM 5–9 dpo, suggesting that IgA could be used at later stages of infection (Appendix Figures 1, 5). Our findings indicate that serologic detection of acute Zika virus infection can be improved ≈2-fold by use of different antibody classes and antigens but remains poorly sensitive in flavivirus-endemic areas.

All Zika virus–infected patients showed IgG responses across the 4 time points in >1 assay (Figure 2, panels C, D). Plaque reduction neutralization tests (PRNTs) were negative for 2 of 14 rRT-PCR–confirmed Zika virus cases detected by NS1-based IgG ELISA. Without rRT-PCR confirmation, these cases would have been classified false positive (Appendix Table 1). This observation might be explained by differential sensitivity of PRNT and ELISA (10) or false-positive results of the Zika virus NS1-based ELISA in secondary flavivirus infections (6). Similarly, the antibody kinetics of Zika virus NS1-based IgG, envelope-based IgG, and PRNT suggested either relatively early IgG seroconversion or cross-reactivity during acute stages of infection resulting from unspecific immune responses against other flaviviruses (11) (Figure 2, panel D). In contrast, CHIKV IgG seroconversion occurred at later stages (Figure 2, panel D; Appendix Figure 5), possibly associated with strong and long-lasting CHIKV-specific IgM responses (Appendix Figure 4).


We provide pivotal data on Zika virus and CHIKV diagnostic challenges in a Latin American setting. Limitations of our study include the relatively small number of patients, sampling at heterogeneous dpo and heterogeneous numbers of samples per dpo, and lack of acutely DENV-infected patients to assess test specificity. The strengths of our study include rRT-PCR–confirmed infections, waiving the need to define serologic assays prone to cross-reactivity as standards, sampling during Zika virus and CHIKV outbreaks (1,2), sequential sampling of patients up to 90 dpo, use of multiple antigens and immunoglobulin classes, and the combination of molecular and serologic testing methods.

Our data suggest reliable diagnostic testing for acute CHIKV infections by IgM detection from 5 dpo onward. This finding might enable waiving labor-intense and costly molecular protocols in many patients, minimizing costs for public health systems and cohort studies investigating arbovirus pathogenesis. However, reliability of CHIKV serologic diagnostic tests must be reevaluated for co-circulating genotypes (12) and for the antigenically related Mayaro virus (13) if it emerges in Latin America.

The difficulties of adequately diagnosing Zika virus infections in areas to which it is endemic have major implications for public health. Reliable testing for flaviviruses in such areas will be key for epidemiologic studies on Zika virus and assessments of the safety of flavivirus vaccination programs, as illustrated by more severe dengue infections in DENV-seronegative individuals who received a live attenuated dengue vaccine (14).

For pregnant women and couples intending pregnancy, accurate diagnosis of acute or past Zika virus infection is crucial. The steep increase in requests for abortion in Latin America illustrates the effect of the Zika virus outbreak on reproductive medicine (15).

Our results highlight that definite exclusion of acute Zika virus infections is challenging in a considerable proportion of patients. However, although limited by a small number of samples, our data highlight the attainability of more accurate Zika virus diagnostic testing by combining molecular and serologic tests using different antibody classes, antigens, and methods and by monitoring an increase of IgG titers in follow-up serum samples. Our data will help clinicians and health authorities build reliable diagnostic algorithms for Zika virus and CHIKV and highlight that exhaustive testing of arboviral infections is required for attributing frequencies of infection-specific symptoms.

Dr. F.A. Bozza is a senior scientist and head of the Laboratório de Medicina Intensiva, Fundação Oswaldo Cruz Rio de Janeiro. His research focuses on the host immune response and metabolic adaptation to severe infections.



We thank Ignacio Postigo-Hidalgo, Jens Miguel Warnecke, and Thiago Carvalho for technical assistance.

This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme through the ZIKAlliance project (grant agreement no. 734548), the German Centre for Infection Research through the ZIKApath project, by the Conselho Nacional de Desenvolvimento e Pesquisa (CNPq) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).



  1. Nunes  MR, Faria  NR, de Vasconcelos  JM, Golding  N, Kraemer  MU, de Oliveira  LF, et al. Emergence and potential for spread of Chikungunya virus in Brazil. BMC Med. 2015;13:102. DOIPubMed
  2. Metsky  HC, Matranga  CB, Wohl  S, Schaffner  SF, Freije  CA, Winnicki  SM, et al. Zika virus evolution and spread in the Americas. Nature. 2017;546:4115. DOIPubMed
  3. Musso  D, Gubler  DJ. Zika Virus. Clin Microbiol Rev. 2016;29:487524. DOIPubMed
  4. Corman  VM, Rasche  A, Baronti  C, Aldabbagh  S, Cadar  D, Reusken  CB, et al. Assay optimization for molecular detection of Zika virus. Bull World Health Organ. 2016;94:88092. DOIPubMed
  5. Netto  EM, Moreira-Soto  A, Pedroso  C, Höser  C, Funk  S, Kucharski  AJ, et al. High Zika virus seroprevalence in Salvador, northeastern Brazil limits the potential for further outbreaks. MBio. 2017;8:0139017. DOIPubMed
  6. Felix  AC, Souza  NCS, Figueiredo  WM, Costa  AA, Inenami  M, da Silva  RMG, et al. Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection. J Med Virol. 2017;89:14779. DOIPubMed
  7. Steinhagen  K, Probst  C, Radzimski  C, Schmidt-Chanasit  J, Emmerich  P, van Esbroeck  M, et al. Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016;21:30426. DOIPubMed
  8. L’Huillier  AG, Hamid-Allie  A, Kristjanson  E, Papageorgiou  L, Hung  S, Wong  CF, et al. Evaluation of Euroimmun anti-Zika virus IgM and IgG enzyme-linked immunosorbent assays for Zika virus serologic testing. J Clin Microbiol. 2017;55:246271. DOIPubMed
  9. Jain  J, Nayak  K, Tanwar  N, Gaind  R, Gupta  B, Shastri  JS, et al. Clinical, serological, and virological analysis of 572 chikungunya patients from 2010 to 2013 in India. Clin Infect Dis. 2017;65:13340. DOIPubMed
  10. Lindsey  NP, Staples  JE, Powell  K, Rabe  IB, Fischer  M, Powers  AM, et al. Ability to serologically confirm recent Zika virus infection in areas with varying past incidence of dengue virus infection in the United States and U.S. territories in 2016. J Clin Microbiol. 2017;56:e011157. DOIPubMed
  11. Priyamvada  L, Quicke  KM, Hudson  WH, Onlamoon  N, Sewatanon  J, Edupuganti  S, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113:78527. DOIPubMed
  12. Weaver  SC, Lecuit  M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015;372:12319. DOIPubMed
  13. Hassing  RJ, Leparc-Goffart  I, Tolou  H, van Doornum  G, van Genderen  PJ. Cross-reactivity of antibodies to viruses belonging to the Semliki forest serocomplex. Euro Surveill. 2010;15:19588.PubMed
  14. World Health Organization. Updated questions and answers related to the dengue vaccine Dengvaxia® and its use [cited 2018 Jan 30].
  15. Aiken  ARA, Scott  JG, Gomperts  R, Trussell  J, Worrell  M, Aiken  CE. Requests for abortion in Latin America related to concern about Zika virus exposure. N Engl J Med. 2016;375:3968. DOIPubMed





Cite This Article

DOI: 10.3201/eid2502.180166

Original Publication Date: 1/7/2019

1These authors contributed equally to this article.

Table of Contents – Volume 25, Number 2—February 2019


Please use the form below to submit correspondence to the authors or contact them at the following address:

Jan Felix Drexler, Helmut-Ruska-Haus, Institute of Virology, Campus Charité Mitte, Charitéplatz 1, 10098 Berlin, Germany

character(s) remaining.

Comment submitted successfully, thank you for your feedback.